Current Problems in Cardiology最新文献

{"title":"Challenges in the diagnosis and management of hypertrophic cardiomyopathy and the promise of artificial intelligence","authors":"Isna H. Khaliq MD ,&nbsp;Aum Solanki MD ,&nbsp;Menhel Kinno MD, MPH ,&nbsp;Annabelle Santos Volgman MD ,&nbsp;Ahmet Afsin Oktay MD","doi":"10.1016/j.cpcardiol.2025.103249","DOIUrl":"10.1016/j.cpcardiol.2025.103249","url":null,"abstract":"<div><div>Hypertrophic cardiomyopathy (HCM), the most prevalent inherited cardiomyopathy, is characterized by left ventricular hypertrophy that typically manifests with asymmetric wall thickening and is not caused by a pressure overload state or systemic disease. Despite its considerable prevalence—estimated to affect up to 1 in 200 individuals based on imaging data—it often goes undiagnosed or misdiagnosed, particularly in general clinical settings. Traditional tools, such as the electrocardiogram, although widely used, frequently yield nonspecific findings that complicate the early identification or screening of HCM. In recent years, artificial intelligence (AI) and machine learning have emerged as powerful tools with the potential to revolutionize HCM diagnosis and management. AI-driven algorithms trained on ECG and imaging data are being developed to improve early detection, risk stratification, and therapeutic monitoring in patients with or at risk for HCM. Additionally, AI has shown utility in biomarker-based prediction models, further enhancing diagnostic precision and clinical decision-making. Harnessing the power of AI may help close critical diagnostic gaps and optimize outcomes for individuals affected by HCM.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"51 3","pages":"Article 103249"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The scope of cardiology research: More than 300 topics covered through bibliometric evaluation","authors":"Saeed Alshahrani ,&nbsp;Siddig Ibrahim Abdelwahab ,&nbsp;Manal Mohamed Elhassan Taha ,&nbsp;Abdullah Farasani ,&nbsp;Jobran M Moshi ,&nbsp;Ahmad Assiri ,&nbsp;Khaled A Sahli ,&nbsp;Hussam M. Shubaily ,&nbsp;Marwa Qadri ,&nbsp;Amani Khardali ,&nbsp;Waseem Hassan","doi":"10.1016/j.cpcardiol.2025.103256","DOIUrl":"10.1016/j.cpcardiol.2025.103256","url":null,"abstract":"<div><div>This study provides a bibliometric overview of cardiovascular-related bibliometric research identified in the Scopus database using a title–abstract–keyword (TAK) search strategy. A total of 2,069 records were identified, with original articles (<em>n</em> = 1,130) and review papers (<em>n</em> = 596) representing the predominant document types. Restricting the analysis to these two categories yielded 1,726 documents, underscoring their central role in bibliometric reporting. A clear temporal growth was observed, increasing from a single publication in 1991 to 71 in 2025, with notable expansion after 2020. Authorship and institutional analyses revealed a strong concentration of contributions from China. Hu Y. was the most prolific author (13 publications), followed by Shou X. (7), while several others contributed five publications each. The China Academy of Chinese Medical Sciences (44 publications) and Beijing University of Chinese Medicine (41) were the leading institutions. China dominated global output with 229 publications, far exceeding the United States (25) and other contributing countries. Funding was primarily provided by the National Natural Science Foundation of China (84 publications). <em>Frontiers in Cardiovascular Medicine</em> was the leading journal (44 publications), followed by <em>Medicine</em> (United States) (28) and <em>Heliyon</em> (18). Thematically, over 300 cardiological subtopics were identified, spanning clinical areas such as heart failure, atrial fibrillation, and obesity-related cardiovascular disease, as well as emerging domains including artificial intelligence, autophagy, ferroptosis, non-coding RNAs, and digital health. Studies also addressed societal and environmental determinants such as gender disparities, air pollution, and psychosocial stress. Collectively, these findings demonstrate the accelerating adoption of bibliometric approaches in cardiovascular science and the field’s transition toward interdisciplinary, technology-integrated, and data-driven research directions.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"51 3","pages":"Article 103256"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Balancing hope and heart: An umbrella review of cardiotoxicity in immune checkpoint inhibitor cancer therapies","authors":"Yashendra Sethi ,&nbsp;Saurabh Singhal ,&nbsp;Apoorv Pratap Singh ,&nbsp;Akshat Banga ,&nbsp;Pratik Agarwal ,&nbsp;Oroshay Kaiwan ,&nbsp;Inderbir Padda ,&nbsp;Aakash Paruthi ,&nbsp;Sneha Annie Sebastian ,&nbsp;Arsalan Moinuddin ,&nbsp;Gurpreet Johal ,&nbsp;Nigel H. Greig","doi":"10.1016/j.cpcardiol.2025.103257","DOIUrl":"10.1016/j.cpcardiol.2025.103257","url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint inhibitors (ICIs) have significantly advanced cancer treatment, especially in improving survival rates for patients with various malignancies such as melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma. Despite their therapeutic promise, ICIs carry the risk of immune-related adverse events, with cardiotoxicity emerging as a notable concern. This umbrella review aims to critically evaluate the diverse data from published systematic reviews and meta-analyses, to provide a cohesive overview of ICI-associated cardiotoxicity across different cancer types and treatment regimens.</div></div><div><h3>Methods</h3><div>This umbrella review analytically evaluates data from systematic reviews and meta-analyses on cardiotoxicity in cancer patients receiving ICI therapy. We conducted a comprehensive search across PubMed, Scopus, and Google Scholar, from inception till Jan 2025. The JBI checklist was employed to assess the quality of included studies.</div></div><div><h3>Results</h3><div>Our analysis reveals varying cardiotoxicity risks associated with ICIs. The incidence of cardiac immune-related adverse events ranges from 0.8 % to 1.3 %, with myocarditis being the most common (0.5-0.72 % of patients). Combination therapies significantly increase risks: dual ICIs elevate myocarditis risk 3.07-fold compared to monotherapies, whereas PD-1/PD-L1 inhibitors with chemotherapy increase all-grade and severe cardiotoxicity by 53 % and 63%, respectively. NSCLC patients face a 97 % higher risk of all-grade cardiotoxicity with combination treatments. ICI-induced myocarditis carries a high mortality rate of 37.7 %. Notably, some studies report no significant increase in cardiac events, highlighting the need for further investigation to reconcile these disparate findings.</div></div><div><h3>Conclusions</h3><div>The variability in cardiotoxicity reports highlights the complex risk landscape associated with ICI therapy. Although ICIs continue to enhance cancer care, they require careful cardiovascular monitoring and comprehensive risk management, particularly for combination therapies and patients with existing heart conditions.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"51 3","pages":"Article 103257"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145829000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiplatelet therapy in patients with chronic coronary syndrome requiring oral anticoagulation: An updated meta-analysis of randomized trials","authors":"Fernando Garagoli ,&nbsp;Walter Masson ,&nbsp;Martin Lobo ,&nbsp;Leandro Barbagelata ,&nbsp;Guillaume Cayla ,&nbsp;Martine Gilard ,&nbsp;Gilles Lemesle","doi":"10.1016/j.cpcardiol.2025.103250","DOIUrl":"10.1016/j.cpcardiol.2025.103250","url":null,"abstract":"<div><h3>Background</h3><div>Patients with chronic coronary syndrome (CCS) often require long-term oral anticoagulation (OAC), most commonly for atrial fibrillation (AF). Evidence on the optimal antithrombotic strategy in this setting remains inconclusive, prompting this updated meta-analysis of randomized trials comparing OAC plus a single antiplatelet therapy (SAPT) with OAC monotherapy.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed/MEDLINE, SciELO, Latindex, LILACS, the Cochrane Library, and ClinicalTrials.gov up to November 12, 2025. The primary efficacy endpoint was all-cause death, while secondary efficacy endpoints included cardiovascular death, acute myocardial infarction, ischemic stroke, and systemic embolism, each analyzed individually. Safety endpoints comprised major and clinically relevant non-major bleeding (International Society on Thrombosis and Hemostasis [ISTH] definition).</div></div><div><h3>Results</h3><div>Six randomized trials including 5,924 participants were analyzed. All-cause death did not differ significantly between OAC plus SAPT and OAC monotherapy (OR 1.31; 95 % CI 0.89–1.92). Dual therapy was associated with an increased risk of cardiovascular death (OR 1.42; 95 % CI 1.05–1.92), whereas rates of myocardial infarction (OR 0.98; 95 % CI 0.60–1.57), ischemic stroke (OR 0.95; 95 % CI 0.64–1.39), and systemic embolism (OR 1.00; 95 % CI 0.20–4.95) were similar between groups. Safety outcomes were markedly worse with dual therapy, which significantly increased the risk of major bleeding (OR 2.20; 95 % CI 1.51–3.22) and major or clinically relevant non-major bleeding (OR 2.30; 95 % CI 1.72–3.06).</div></div><div><h3>Conclusions</h3><div>In patients with CCS requiring long-term OAC, dual therapy (OAC plus SAPT) did not reduce all-cause death nor ischemic events compared with OAC alone but significantly increased major bleeding and cardiovascular death. <strong>PROSPERO Registration No.: CRD420251239917.</strong></div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"51 3","pages":"Article 103250"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of concurrent training on atrial fibrillation burden, fitness and physical activity after pulmonary vein isolation: Study protocol for a randomized controlled trial","authors":"Marcos Echevarría-Polo MSc ,&nbsp;Adrián Hernández-Vicente PhD ,&nbsp;Pablo Vadillo-Martín MD,MSc ,&nbsp;Fabian Sanchis-Gomar MD, PhD ,&nbsp;Jorge Melero-Polo MD ,&nbsp;Mercedes Cabrera-Ramos MD ,&nbsp;Isabel Montilla-Padilla MD ,&nbsp;Andrea Rucco MSc ,&nbsp;Juan Pablo Martínez PhD ,&nbsp;Pablo Laguna PhD ,&nbsp;Esther Pueyo PhD ,&nbsp;Javier Ramos-Maqueda MD, PhD ,&nbsp;Nuria Garatachea PhD","doi":"10.1016/j.cpcardiol.2025.103218","DOIUrl":"10.1016/j.cpcardiol.2025.103218","url":null,"abstract":"<div><h3>Background</h3><div>Pulmonary vein isolation (PVI) is an effective treatment for atrial fibrillation (AF), but many patients remain inactive after the procedure for fear of AF recurrence. Evidence supports moderate exercise to improve outcomes of this procedure; however, there are no clear guidelines for returning to physical exercise after PVI. We aim to evaluate the effects of a combined endurance and resistance training (CT) intervention on cardiac function, physical fitness, activity levels, body composition, quality of life, and AF burden after PVI.</div></div><div><h3>Methods and results</h3><div>We will conduct a randomized controlled trial with 68 participants, approximately 15 months after PVI, randomized 1:1 to a CT or control group. The CT program consists of supervised training sessions combining moderate-intensity endurance and resistance work three times a week for 12 weeks. Outcomes will be assessed at three time points: at baseline, after the intervention, and after 12 weeks of follow-up, including echocardiographic and electrocardiographic parameters, fitness tests, physical activity monitoring, body composition, health-related quality of life, and AF burden monitored by an implantable cardiac Holter. We expect that CT intervention will improve cardiac function, increase physical fitness and activity levels, optimize body composition, and improve quality of life without recurrence of AF.</div></div><div><h3>Conclusions</h3><div>This protocol is the first to examine the effects of return to exercise training in AF patients after PVI using objective monitoring tools. The simplicity and scalability of the intervention support its safe integration into clinical practice to promote physical activity and improve patient outcomes after PVI.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"51 3","pages":"Article 103218"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145642326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title Page","authors":"","doi":"10.1016/S0146-2806(26)00021-6","DOIUrl":"10.1016/S0146-2806(26)00021-6","url":null,"abstract":"","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"51 3","pages":"Article 103279"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146077586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The early initiation of sodium-glucose cotransporter-2 inhibitors in patients with decompensated heart failure: A systematic review and meta-analysis","authors":"Ahmad Al-Abdouh MD ,&nbsp;Ahmad Jabri MD ,&nbsp;Mohammed Mhanna MD ,&nbsp;Laith Alhuneafat MD ,&nbsp;Fares Ghanem MD ,&nbsp;Ibrahim Mortada MD ,&nbsp;Omar Obeidat MD ,&nbsp;Shareef Mansour MD ,&nbsp;Wissam Khalife MD","doi":"10.1016/j.cpcardiol.2025.103255","DOIUrl":"10.1016/j.cpcardiol.2025.103255","url":null,"abstract":"<div><h3>Introduction</h3><div>Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown significant reduction in cardiovascular mortality and heart failure hospitalization in patients with chronic heart failure. Despite their benefits in chronic heart failure, their use during episodes of acute decompensation remains under investigation.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was performed using PubMed, Google Scholar, and ClinicalTrials.gov from database inception through September 3, 2025. The predefined endpoints were all-cause mortality, heart failure hospitalizations, and a composite of cardiovascular mortality or heart failure worsening. Outcomes were pooled using a random effects Mantel-Haenszel model. The DerSimonian and Laird method was used for estimation of τ.² We reported effect sizes as risk ratios (RR) with 95 % confidence interval (CI).</div></div><div><h3>Results</h3><div>A total of eight randomized controlled trials, encompassing 4,714 patients, were included in the analysis. Among patients hospitalized with decompensated heart failure, treatment with SGLT2 inhibitors compared with standard care only (control group) was associated with a significant decrease in all-cause mortality (RR 0.72; 95 % CI, 0.58–0.90; <em>P</em> &lt; 0.01; I² = 0 %), and in the composite outcome of cardiovascular mortality or heart failure rehospitalization (RR 0.68; 95 % CI, 0.53–0.86; <em>P</em> &lt; 0.01; I² = 28 %). However, no significant reduction was observed in heart failure rehospitalization as an isolated outcome (RR 0.92; 95 % CI, 0.82–1.03; <em>P</em> = 0.16; I² = 0 %).</div></div><div><h3>Conclusion</h3><div>SGLT-2 inhibitors during hospitalization for acute decompensated heart failure is effective and led to decrease in all-cause mortality and a composite endpoint of cardiovascular mortality or heart failure hospitalizations.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"51 3","pages":"Article 103255"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress on application of exosomes on cardiovascular disease: A ten-year retrospective analysis","authors":"Zichun Tang MD ,&nbsp;Shuang Feng MD ,&nbsp;Zongwei Xiao","doi":"10.1016/j.cpcardiol.2025.103211","DOIUrl":"10.1016/j.cpcardiol.2025.103211","url":null,"abstract":"<div><h3>Background</h3><div>Exosomes, nanoscale extracellular vesicles (30–150 nm) carrying bioactive molecules (e.g., miRNAs, proteins), have emerged as pivotal mediators in cardiovascular diseases (CVDs), offering potential as diagnostic biomarkers and therapeutic vectors. Despite growing interest, a comprehensive analysis of global research trends, hotspots, and translational gaps in exosome applications for CVDs remains limited.</div></div><div><h3>Methods</h3><div>We conducted a ten-year (2016–2025) bibliometric analysis of 2617 publications from the Web of Science Core Collection, employing integrative tools (LDGAS and KMVS) to map research distribution, collaborations, and citation trends. Data was analyzed for contributions by country, institution, journal, and author, with a focus on mechanistic insights, clinical applications, and technological innovations.</div></div><div><h3>Results</h3><div>Global publications surged post-2016, with China leading in output (50 % of top institutions) and the USA/Europe dominating citation impact (e.g., Harvard Medical School: 7.83 citations/paper). Three key themes emerged: exosomal regulation of oxidative stress, inflammation, and angiogenesis; engineered exosomes (e.g., inflammation-targeting macrophage exosomes and stem cell-derived exosomes; circulating miRNAs (e.g., miR-21-5p in heart failure). Challenges include heterogeneous exosome isolation methods (&lt;5 % studies reach preclinical trials) and imbalanced collaborations (China-USA partnerships dominated, 83 %).</div></div><div><h3>Conclusions</h3><div>Exosome research in CVDs demonstrates transformative potential but requires standardized protocols, diversified clinical trials, and strengthened global partnerships. Prioritizing AI-driven biomarker discovery and interdisciplinary synergy will accelerate clinical translation.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"51 3","pages":"Article 103211"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145645756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological health in a modified life’s Crucial 9 score: Association with all-cause mortality and comparison with LE8","authors":"Felipe Diaz-Toro PhD ,&nbsp;Víctor Pedrero PhD ,&nbsp;Gabriela Nazar PhD ,&nbsp;Daniel Reyes-Molina PhD ,&nbsp;Yeny Concha-Cisternas PhD ,&nbsp;Fabian Lanuza PhD ,&nbsp;Carlos Celis-Morales PhD ,&nbsp;Fanny Petermann-Rocha PhD","doi":"10.1016/j.cpcardiol.2025.103219","DOIUrl":"10.1016/j.cpcardiol.2025.103219","url":null,"abstract":"<div><h3>Background</h3><div>The inclusion of Psychological Health in the Life’s Essential 8 (LE8) may improve its predictive validity and contribute to a more equitable assessment of mortality by better accounting for this crucial component. Therefore, this study aimed i) to assess the longitudinal association between a modified version of Life’s Crucial 9 (LC9) score and all-cause mortality in the Chilean population and ii) to examine whether adding psychological health to the original LE8 framework might enhance its predictive ability.</div></div><div><h3>Method</h3><div>We included 3,546 participants aged ≥15 from the Chilean National Health Survey 2016–2017. Mortality was ascertained through linkage with the Chilean Civil Registry and Identification. A modified version of the LC9 score was created and divided into quartiles. The modified version was calculated from nine health and behavioral components, incorporating a Psychological Health variable (composite of depression and social integration). The association between LC9 and all-cause mortality was examined using crude Kaplan-Meier survival curves and Cox proportional hazard models adjusted for sociodemographic and lifestyle factors. Non-linear associations were explored using restricted cubic splines. Predictive performance of LC9 was further compared with LE8 using model fit criteria (AIC, BIC) and discrimination measures (C-statistics, ROC-AUC).</div></div><div><h3>Findings</h3><div>Over a median follow-up of 5 years, 169 participants (4.8 %) died from any cause. Survival curves showed lower survival probabilities among individuals in the lowest LC9 quartile than to those in higher quartiles (log-rank &lt;0.001). Compared with participants in Q1, those in Q4 had a 49 % lower risk of all-cause mortality after full adjustment for confounders (HR: 0.51; 95 % CI: 0.31–0.82). When comparing indices, LC9 (C-statistics= 0.854 (95 % CI: 0.842-0.866) provided marginally better model fit than LE8 (C-statistics= 0.851 (95 % CI: 0.839-0.864), but their overall predictive performance for mortality was similar.</div></div><div><h3>Interpretation</h3><div>Higher LC9 scores were associated with lower all-cause mortality. The incorporation of Psychological Health measures may slightly improve the prediction of the models.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"51 3","pages":"Article 103219"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145642433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physiological and metabolic predictors of adverse outcomes one year after coronary intervention: A two-tiered approach","authors":"Yuxiang Chen MM ,&nbsp;Jiaxin Zhong MM ,&nbsp;Beilei Li MM ,&nbsp;Ruijin Hong MM ,&nbsp;Hui Chen MM ,&nbsp;Lianglong Chen MD ,&nbsp;Yuanming Yan MD ,&nbsp;Yukun Luo MD ,&nbsp;Qin Chen MD","doi":"10.1016/j.cpcardiol.2025.103212","DOIUrl":"10.1016/j.cpcardiol.2025.103212","url":null,"abstract":"<div><h3>Background</h3><div>Residual ischemia and metabolic dysregulation remain determinants of long-term prognosis after percutaneous coronary intervention (PCI). We investigated the prognostic impact of the three-vessel quantitative flow ratio (3V-QFR) and the triglyceride–glucose (TyG) index in this population.</div></div><div><h3>Methods</h3><div>A total of 546 patients who underwent repeat angiography one year after PCI were followed for four years. Restricted cubic spline analysis was used to determine risk thresholds for both 3V-QFR and TyG. The primary endpoint was major adverse cardiac events (MACEs).</div></div><div><h3>Results</h3><div>The optimal cutoffs for predicting MACEs were 2.44 for 3V-QFR and 8.75 for TyG. Patients with 3V-QFR &lt; 2.44 experienced significantly higher adverse event rates. Among patients with 3V-QFR ≥ 2.44, TyG ≥ 8.75 was independently associated with increased MACEs (adjusted HR 1.51, 95 % CI 1.04–2.05), mainly driven by ischemia-driven revascularization. No such association was observed in patients with 3V-QFR &lt; 2.44.</div></div><div><h3>Conclusions</h3><div>3V-QFR &lt; 2.44 reflects residual functional ischemia and portends poor prognosis after PCI. In patients with complete functional revascularization, a high TyG index indicates elevated metabolic risk. A combined physiological–metabolic assessment provides improved risk stratification for long-term secondary prevention.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"51 3","pages":"Article 103212"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145642447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}